JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.
Aicardi-Goutières syndrome (AGS)
JAK inhibitors
interferon
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
05
12
2022
accepted:
19
04
2023
medline:
21
7
2023
pubmed:
12
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
The paradigm type I interferonopathy Aicardi-Goutières syndrome (AGS) is most typically characterized by severe neurological involvement. AGS is considered an immune-mediated disease, poorly responsive to conventional immunosuppression. Premised on a chronic enhancement of type I interferon signaling, JAK1/2 inhibition has been trialed in AGS, with clear improvements in cutaneous and systemic disease manifestations. Contrastingly, treatment efficacy at the level of the neurological system has been less conclusive. Here, we report our real-word approach study of JAK1/2 inhibition in 11 patients with AGS, providing extensive assessments of clinical and radiological status; interferon signaling, including in cerebrospinal fluid (CSF); and drug concentrations in blood and CSF. Over a median follow-up of 17 months, we observed a clear benefit of JAK1/2 inhibition on certain systemic features of AGS, and reproduced results reported using the AGS neurologic severity scale. In contrast, there was no change in other scales assessing neurological status; using the caregiver scale, only patient comfort, but no other domain of everyday-life care, was improved. Serious bacterial infections occurred in 4 out of the 11 patients. Overall, our data lead us to conclude that other approaches to treatment are urgently required for the neurologic features of AGS. We suggest that earlier diagnosis and adequate central nervous system penetration likely remain the major factors determining the efficacy of therapy in preventing irreversible brain damage, implying the importance of early and rapid genetic testing and the consideration of intrathecal drug delivery.
Identifiants
pubmed: 37171742
doi: 10.1007/s10875-023-01500-z
pii: 10.1007/s10875-023-01500-z
pmc: PMC10175907
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1436-1447Subventions
Organisme : Medical Research Council
ID : U127580972
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s).
Références
Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. Nat Rev Immunol. 2021;
Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GMA, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167A:296–312.
doi: 10.1002/ajmg.a.36887
pubmed: 25604658
Livingston JH, Lin J-P, Dale RC, Gill D, Brogan P, Munnich A, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet. 2014;51:76–82.
doi: 10.1136/jmedgenet-2013-102038
pubmed: 24262145
D’Arrigo S, Riva D, Bulgheroni S, Chiapparini L, Lebon P, Rice G, et al. Aicardi-Goutières syndrome: description of a late onset case. Dev Med Child Neurol. 2008;50:631–4.
doi: 10.1111/j.1469-8749.2008.03033.x
pubmed: 18754903
Volkman HE, Stetson DB. The enemy within: endogenous retroelements and autoimmune disease. Nat Immunol. 2014;15:415–22.
doi: 10.1038/ni.2872
pubmed: 24747712
pmcid: 4131434
Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M, et al. Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome. N Engl J Med. 2018;379:2275–7.
doi: 10.1056/NEJMc1810983
pubmed: 30566312
Kothur K, Bandodkar S, Chu S, Wienholt L, Johnson A, Barclay P, et al. An open-label trial of JAK 1/2 blockade in progressive IFIH1-associated neuroinflammation. Neurology. 2018;90:289–91.
doi: 10.1212/WNL.0000000000004921
pubmed: 29321238
Vanderver A, Adang L, Gavazzi F, McDonald K, Helman G, Frank DB, et al. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. N Engl J Med. 2020;383:986–9.
doi: 10.1056/NEJMc2001362
pubmed: 32877590
pmcid: 7495410
McLellan KE, Martin N, Davidson JE, Cordeiro N, Oates BD, Neven B, et al. JAK 1/2 Blockade in MDA5 Gain-of-Function. J Clin Immunol. 2018;38:844–6.
doi: 10.1007/s10875-018-0563-2
pubmed: 30443754
Briand C, Frémond M-L, Bessis D, Carbasse A, Rice GI, Bondet V, et al. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Ann Rheum Dis. 2019;78:431–3.
doi: 10.1136/annrheumdis-2018-214037
pubmed: 30282666
Zheng S, Lee PY, Wang J, Wang S, Huang Q, Huang Y, et al. Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome. Front Immunol. 2020;11:985.
doi: 10.3389/fimmu.2020.00985
pubmed: 32508843
pmcid: 7251162
Broser P, von Mengershausen U, Heldt K, Bartholdi D, Braun D, Wolf C, et al. Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report. Pediatr Rheumatol Online J. 2022;20:24.
doi: 10.1186/s12969-022-00686-7
pubmed: 35410415
pmcid: 8995680
Neven B, Al Adba B, Hully M, Desguerre I, Pressiat C, Boddaert N, et al. JAK Inhibition in the Aicardi-Goutières Syndrome. N Engl J Med. 2020;383:2190–1.
doi: 10.1056/NEJMc2031081
pubmed: 33252884
Adang LA, Gavazzi F, Jawad AF, Cusack SV, Kopin K, Peer K, et al. Development of a neurologic severity scale for Aicardi Goutières Syndrome. Mol Genet Metab. 2020;130:153–60.
doi: 10.1016/j.ymgme.2020.03.008
pubmed: 32279991
pmcid: 7366613
Rousseau MC, Baumstarck K, Hamouda I, Valkov M, Felce A, Khaldi-Cherif S, et al. Development and initial validation of the polyhandicap severity scale. Rev Neurol. 2021;177:683–9.
doi: 10.1016/j.neurol.2020.06.018
pubmed: 33069376
Barry MJ, VanSwearingen JM, Albright AL. Reliability and responsiveness of the Barry-Albright Dystonia Scale. Dev Med Child Neurol. 1999;41:404–11.
doi: 10.1017/S0012162299000870
pubmed: 10400175
Battini R, Sgandurra G, Petacchi E, Guzzetta A, Di Pietro R, Giannini MT, et al. Movement disorder-childhood rating scale: reliability and validity. Pediatr Neurol. 2008;39:259–65.
doi: 10.1016/j.pediatrneurol.2008.07.002
pubmed: 18805364
Battini R, Guzzetta A, Sgandurra G, Di Pietro R, Petacchi E, Mercuri E, et al. Scale for evaluation of movement disorders in the first three years of life. Pediatr Neurol. 2009;40:258–64.
doi: 10.1016/j.pediatrneurol.2008.11.003
pubmed: 19302937
Schneider JW, Gurucharri LM, Gutierrez AL, Gaebler-Spira DJ. Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol. 2001;43:601–8.
doi: 10.1017/S0012162201001098
pubmed: 11570628
Rice GI, Forte GMA, Szynkiewicz M, Chase DS, Aeby A, Abdel-Hamid MS, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12:1159–69.
doi: 10.1016/S1474-4422(13)70258-8
pubmed: 24183309
pmcid: 4349523
Lepelley A, Martin-Niclós MJ, Le Bihan M, Marsh JA, Uggenti C, Rice GI, et al. Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. J Exp Med. 2020;217
Rodero MP, Decalf J, Bondet V, Hunt D, Rice GI, Werneke S, et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med. 2017;214:1547–55.
doi: 10.1084/jem.20161451
pubmed: 28420733
pmcid: 5413335
Ormazabal A, García-Cazorla A, Fernández Y, Fernández-Alvarez E, Campistol J, Artuch R. HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins. J Neurosci Methods. 2005;142:153–8.
doi: 10.1016/j.jneumeth.2004.08.007
pubmed: 15652629
Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, et al. Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients. Clin Pharmacol Ther. 2018;104:364–73.
doi: 10.1002/cpt.936
pubmed: 29134648
Frémond M-L, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138:1752–5.
doi: 10.1016/j.jaci.2016.07.015
pubmed: 27554814
Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041–52.
doi: 10.1172/JCI98814
pubmed: 29649002
pmcid: 6026004
Frémond M-L, Hadchouel A, Berteloot L, Melki I, Bresson V, Barnabei L, et al. Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. J Allergy Clin Immunol Pract. 2021;9:803–818.e11.
doi: 10.1016/j.jaip.2020.11.007
pubmed: 33217613
Hadjadj J, Frémond M-L, Neven B. Emerging place of JAK inhibitors in the treatment of inborn errors of immunity. Front Immunol. 2021;12:717388.
doi: 10.3389/fimmu.2021.717388
pubmed: 34603291
pmcid: 8484879
Mollé N, Krichevsky S, Kermani P, Silver RT, Ritchie E, Scandura JM. Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood. 2020;135:1062–6.
pubmed: 32047890
Tonduti D, Izzo G, D’Arrigo S, Riva D, Moroni I, Zorzi G, et al. Spontaneous MRI improvement and absence of cerebral calcification in Aicardi-Goutières syndrome: Diagnostic and disease-monitoring implications. Mol Genet Metab. 2019;126:489–94.
doi: 10.1016/j.ymgme.2019.02.006
pubmed: 30826161
Adang LA, Frank DB, Gilani A, Takanohashi A, Ulrick N, Collins A, et al. Aicardi goutières syndrome is associated with pulmonary hypertension. Mol Genet Metab. 2018;125:351–8.
doi: 10.1016/j.ymgme.2018.09.004
pubmed: 30219631
pmcid: 6880931
Low AT, Howard L, Harrison C, RMR T. Pulmonary arterial hypertension exacerbated by ruxolitinib. Haematologica. 2015;100:e244–5.
doi: 10.3324/haematol.2014.120816
pubmed: 25682609
pmcid: 4450640
Adang LA, Gavazzi F, D’Aiello R, Isaacs D, Bronner N, Arici ZS, et al. Hematologic abnormalities in Aicardi Goutières Syndrome. Mol Genet Metab. 2022;
Bijker EM, Rösler B, Hoppenreijs E, Henriet S, van der Flier M. Functional Asplenia and Specific Polysaccharide Antibody Deficiency in a Girl with SAVI. J Clin Immunol. 2021;41:495–7.
doi: 10.1007/s10875-020-00929-w
pubmed: 33230617
Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86:1188–91.
doi: 10.4065/mcp.2011.0518
pubmed: 22034658
pmcid: 3228619
Adang L, Gavazzi F, De Simone M, Fazzi E, Galli J, Koh J, et al. Developmental outcomes of aicardi goutières syndrome. J Child Neurol. 2020;35:7–16.
doi: 10.1177/0883073819870944
pubmed: 31559893
Rice GI, Kitabayashi N, Barth M, Briggs TA, Burton ACE, Carpanelli ML, et al. Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. Neuropediatrics. 2017;48:166–84.
doi: 10.1055/s-0037-1601449
pubmed: 28561207
pmcid: 5985975
Rice GI, Park S, Gavazzi F, Adang LA, Ayuk LA, Van Eyck L, et al. Genetic and phenotypic spectrum associated with IFIH1 gain-of-function. Hum Mutat. 2020;41:837–49.
doi: 10.1002/humu.23975
pubmed: 31898846
pmcid: 7457149
Steenbeek D, Ketelaar M, Galama K, Gorter JW. Goal attainment scaling in paediatric rehabilitation: a critical review of the literature. Dev Med Child Neurol. 2007;49:550–6.
doi: 10.1111/j.1469-8749.2007.00550.x
pubmed: 17593130
Lodi L, Melki I, Bondet V, Seabra L, Rice GI, Carter E, et al. Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies. J Clin Immunol. 2021;41:603–9.
doi: 10.1007/s10875-020-00952-x
pubmed: 33411153
Han VX, Mohammad SS, Jones HF, Bandodkar S, Crow YJ, Dale RC, et al. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Goutières syndrome. Dev Med Child Neurol. 2022;64:266–71.
doi: 10.1111/dmcn.15025
pubmed: 34415581
Izzotti A, Fazzi E, Orcesi S, Cartiglia C, Longobardi M, Capra V, et al. Brain damage as detected by cDNA-microarray in the spinal fluid of patients with Aicardi-Goutieres syndrome. Neurology. 2008;71:610–2.
doi: 10.1212/01.wnl.0000313934.05965.71
pubmed: 18596240
Crow YJ, Neven B, Frémond M-L. JAK inhibition in the type I interferonopathies. J Allergy Clin Immunol. 2021;148:991–3.
doi: 10.1016/j.jaci.2021.07.028
pubmed: 34375617